The Centers for Medicare & Medicaid Services (CMS) released its fourth COVID-19 interim final rule (IFC), which includes several provisions to prepare for coverage of forthcoming vaccines and treatments for the disease (press release; fact sheet).
Briefly, the new rule outlines policy changes in the following key areas:
- COVID-19 Vaccines: The rule implements coverage policies for vaccines and their administration for Medicare, Medicaid, and CHIP beneficiaries.
- COVID-19 Treatments: The IFC also implements Medicare payment policies for authorized COVID-19 treatments in the inpatient and outpatient settings.
- Price Transparency: CMS is requiring providers to publicly display the cash price for COVID-19 diagnostic tests.
- Additional Provisions: The IFC contains a number of other related changes, including those pertaining to –
- Coverage of COVID-19 preventive services;
- Extension of the CMS Comprehensive Joint Replacement model;
- Revisions to Section 1332 waiver policy; and
- Changes to rules around states receiving increases in their federal medical assistance percentage (FMAP) during the COVID-19 public health emergency (PHE).